Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | OGG1 | O15527 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17544847 | 1.00 | ALDH1A1 (0.38) | ALDH1A1GAAOGG1HIF1ACA1 | |
| SCHEMBL22101804 | 0.79 | — | — | |
| SCHEMBL20204373 | 0.79 | — | — | |
| SCHEMBL15717701 | 0.78 | APLNR (0.31) | — | |
| SCHEMBL8221420 | 0.78 | APLNR (0.31) | — | |
| SCHEMBL25176906 | 0.78 | APLNR (0.31) | — | |
| SCHEMBL1741600 | 0.76 | SMN1; SMN2 (0.35) | ALDH1A1CA1CA2 | |
| SCHEMBL1741146 | 0.76 | SMN1; SMN2 (0.35) | ALDH1A1CA1CA2 | |
| SCHEMBL1741149 | 0.76 | SMN1; SMN2 (0.35) | ALDH1A1CA1CA2 | |
| SCHEMBL1369677 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3691638-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| EP-3237411-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3237411-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-06-09 | — | — | US | disclosed |
| CN-107207487-B | Compounds, compositions and methods for increasing CFTR activity | 蛋白质平衡治疗股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-20210369749-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210369749-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| US-11083709-B2 | Compounds, compositions, and methods of increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20160083412-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
| WO-2015196071-A9 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2015196071-A9 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2015196071-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015196071-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-9175031-B2 | Ketolide compounds | WOCKHARDT LIMITED (IN) | 2015-11-03 | — | — | US | disclosed |
| US-9175031-B2 | Ketolide compounds | WOCKHARDT LIMITED (IN) | 2015-11-03 | — | — | US | disclosed |
| US-20140005133-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2014-01-02 | — | — | US | disclosed |
| EP-2673285-A1 | KETOLIDE COMPOUNDS | Wockhardt Limited (IN) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012076989-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369749-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, ATP5ME | ALDH1A1 3426/4885GAA 84/4885OGG1 1353/4885 |
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | ALDH1A1 813/4885GAA 108/4885OGG1 1564/4885 |
| US-20160083412-A1 | KETOLIDE COMPOUNDS | AKR1C3, AKR1D1, AKR1C1 | ALDH1A1 2446/4885GAA 3524/4885OGG1 2881/4885 |
| US-20140005133-A1 | KETOLIDE COMPOUNDS | AKR1C3, AKR1D1, AKR1C1 | ALDH1A1 2322/4885GAA 3455/4885OGG1 2711/4885 |
| US-11083709-B2 | Compounds, compositions, and methods of increasing CFTR activity | CFTR, ABCB4, SCNN1B | ALDH1A1 3001/4885GAA 113/4885OGG1 2158/4885 |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | ALDH1A1 813/4885GAA 108/4885OGG1 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.